These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22406118)

  • 21. Synthesis and anti-HIV activity of different novel nonclassical nucleosides.
    Elgemeie GE; Mansour OA; Metwally NH
    Nucleosides Nucleotides; 1999 Jan; 18(1):113-23. PubMed ID: 10048227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.
    Forssmann WG; The YH; Stoll M; Adermann K; Albrecht U; Tillmann HC; Barlos K; Busmann A; Canales-Mayordomo A; Giménez-Gallego G; Hirsch J; Jiménez-Barbero J; Meyer-Olson D; Münch J; Pérez-Castells J; Ständker L; Kirchhoff F; Schmidt RE
    Sci Transl Med; 2010 Dec; 2(63):63re3. PubMed ID: 21178138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.
    Shimane K; Kodama EN; Nakase I; Futaki S; Sakurai Y; Sakagami Y; Li X; Hattori T; Sarafianos SG; Matsuoka M
    Int J Biochem Cell Biol; 2010 Sep; 42(9):1482-8. PubMed ID: 20580677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and anti-HIV activity of novel 3-substituted phenyl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]isoxazole analogues.
    Ali MA; Ismail R; Choon TS; Yoon YK; Wei AC; Pandian S; Samy JG; De Clercq E; Pannecouque C
    Acta Pol Pharm; 2011; 68(3):343-8. PubMed ID: 21648188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro anti-HIV and antitumor activity of new 3,6-disubstituted [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and thiadiazine analogues.
    Al-Soud YA; Al-Masoudi NA; Loddo R; La Colla P
    Arch Pharm (Weinheim); 2008 Jun; 341(6):365-9. PubMed ID: 18493972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and anti-HIV activity evaluation of novel 2,4-disubstituted 7-methyl-1,1,3-trioxo-2,4-dihydro-pyrazolo-[4,5-e][1,2]thiadiazines.
    Liu XY; Yan RZ; Wang Y; Zhan P; De Clercq E; Pannecouque C; Witvrouw M; Molina MT; Vega S
    Arch Pharm (Weinheim); 2008 Apr; 341(4):216-22. PubMed ID: 18266290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
    Herrera E; Tenckhoff S; Gómara MJ; Galatola R; Bleda MJ; Gil C; Ercilla G; Gatell JM; Tillmann HL; Haro I
    J Med Chem; 2010 Aug; 53(16):6054-63. PubMed ID: 20718496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of receptors in the HIV-1 entry process.
    Jones R; Nelson M
    Eur J Med Res; 2007 Oct; 12(9):391-6. PubMed ID: 17933719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
    Robinson WE; Cordeiro M; Abdel-Malek S; Jia Q; Chow SA; Reinecke MG; Mitchell WM
    Mol Pharmacol; 1996 Oct; 50(4):846-55. PubMed ID: 8863829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.
    Rashad AA; Kalyana Sundaram RV; Aneja R; Duffy C; Chaiken I
    J Med Chem; 2015 Sep; 58(18):7603-8. PubMed ID: 26331669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors.
    Rudick JG; Laakso MM; Schloss AC; DeGrado WF
    Org Biomol Chem; 2013 Nov; 11(41):7096-100. PubMed ID: 24065278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity.
    Jia R; Ding S; Pan Q; Liu SL; Qiao W; Liang C
    PLoS One; 2015; 10(3):e0118794. PubMed ID: 25738301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of anti-HIV peptides based on a viral capsid protein.
    Mizuguchi T; Ohashi N; Matsumoto D; Hashimoto C; Nomura W; Yamamoto N; Murakami T; Tamamura H
    Biopolymers; 2017 Jan; 108(1):. PubMed ID: 27428649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-density lipoprotein receptor-related protein 1 mediates α1-antitrypsin internalization in CD4+ T lymphocytes.
    Zhou X; Liu Z; Shapiro L; Yang J; Burton GF
    J Leukoc Biol; 2015 Dec; 98(6):1027-35. PubMed ID: 26206901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of some peptides corresponding to the active region of RANTES for chemotaxis and evaluation of their anti-human immunodeficiency virus-1 activity.
    Nishiyama Y; Murakami T; Kurita K; Yamamoto N
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2125-8. PubMed ID: 9433785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.
    Mizuguchi T; Ohashi N; Nomura W; Komoriya M; Hashimoto C; Yamamoto N; Murakami T; Tamamura H
    Bioorg Med Chem; 2015 Aug; 23(15):4423-4427. PubMed ID: 26094944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.
    Tamamura H; Waki M; Imai M; Otaka A; Ibuka T; Waki K; Miyamoto K; Matsumoto A; Murakami T; Nakashima H; Yamamoto N; Fujii N
    Bioorg Med Chem; 1998 Apr; 6(4):473-9. PubMed ID: 9597190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.